Influence of nebivolol and metoprolol on inflammatory mediators in human coronary endothelial or smooth muscle cells. Effects on neointima formation after balloon denudation in carotid arteries of rats treated with nebivolol

Cellular Physiology and Biochemistry

Volumn 19, Issue 1-4, 2007, Pages 129-136

  Wolf, Sabine C ^a   Sauter, Gabriele ^a   Preyer, Maria ^a   Poerner, Tudor ^c   Kempf, Volkhard A J ^b   Risler, Teut ^a   Brehm, Bernhard R ^a,c  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

Atherosclerosis, carotid arteries; Endothelial cell, blocker; Muscle, smooth

Indexed keywords

INTERCELLULAR ADHESION MOLECULE 1; MESSENGER RNA; METOPROLOL TARTRATE; NEBIVOLOL; PADGEM PROTEIN; PLATELET DERIVED GROWTH FACTOR B; PLATELET DERIVED GROWTH FACTOR BB; VASCULAR CELL ADHESION MOLECULE 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ATHEROSCLEROTIC PLAQUE; CAROTID ARTERY INJURY; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; ENDOTHELIUM CELL; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SMOOTH MUSCLE FIBER; SPRAGUE DAWLEY RAT; TREATMENT DURATION;

RATTUS;

EID: 33847066767     PISSN: 10158987     EISSN: None     Source Type: Journal    
DOI: 10.1159/000099201     Document Type: Article

References (32)

1. Stocker R, Keaney JF, Jr.: Role of oxidative modifications in atherosclerosis. Physiol Rev 2004;84:1381-1478.
2. Andres V: Control of vascular smooth muscle cell growth and its implication in atherosclerosis and restenosis (review). Int J Mol Med 1998;2:81-89.
3. Olsson G, Wikstrand J, Warnold I, Manger Cats V, McBoyle D, Herlitz J, Hjalmarson A, Sonneblick EH: Metoprolol-induced reduction in postinfarction mortality: pooled results from five double-blind randomized trials. Eur Heart J 1992;13:28-32.
4. Linden T, Camejo G, Wiklund O, Warnold I, Olofsson SO, Bondjers G: Effect of short-term beta blockade on serum lipid levels and on the interaction of LDL with human arterial proteoglycans. J Clin Pharmacol 1990;30:S124-131.
5. Pettersson K, Bejne B, Bjork H, Strawn WB, Bondjers G: Experimental sympathetic activation causes endothelial injury in the rabbit thoracic aorta via beta 1-adrenoceptor activation. Circ Res 1990;67:1027-1034.
6. Skantze HB, Kaplan J, Pettersson K, Manuck S, Blomqvist N, Kyes R, Williams K, Bondjers G: Psychosocial stress causes endothelial injury in cynomolgus monkeys via beta1-adrenoceptor activation. Atherosclerosis 1998;136:153-161.
7. Kaplan JR, Manuck SB, Adams MR, Weingand KW, Clarkson TB: Inhibition of coronary atherosclerosis by propranolol in behaviorally predisposed monkeys fed an atherogenic diet. Circulation 1987;76:1364-1372.
8. Cockcroft JR, Chowienczyk PJ, Brett SE, Chen CP, Dupont AG, Van Nueten L, Wooding SJ, Ritter JM: Nebivolol vasodilates human forearm vasculature: evidence for an L- arginine/NO-dependent mechanism. J Pharmacol Exp Ther 1995;274:1067-1071.
9. Tzemos N, Lim PO, MacDonald TM: Nebivolol reverses endothelial dysfunction in essential hypertension: a randomized, double-blind, crossover study. Circulation 2001;104:511-514.
10. Brehm BR, Wolf SC, Bertsch D, Klaussner M, Wesselborg S, Schulze Osthoff K: Effects of nebivolol on proliferation and apoptosis on human coronary artery smooth muscle and endothelical cells. Cardiovasc Res 2001;49:430-439.
11. Livak KJ, Schmittgen TD: Analysis of relative gene expression data using realtime quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001;25:402-408.
12. Clowes AW, Reidy MA, Clowes MM: Kinetics of cellular proliferation after arterial injury. I. Smooth muscle growth in the absence of endothelium. Lab Invest 1983;49:327-333.
13. Cybulsky MI, Iiyama K, Li H, Zhu S, Chen M, Iiyama M, Davis V, Gutierrez-Ramos JC, Connelly PW, Milstone DS: A major role for VCAM-1, but not ICAM-1, in early atherosclerosis. J Clin Invest 2001;107:1255-1262.
14. Cybulsky MI, Gimbrone MA, Jr.: Endothelial expression of a mononuclear leukocyte adhesion molecule during atherogenesis. Science 1991;251:788-791.
15. Johnson RC, Chapman SM, Dong ZM, Ordovas JM, Mayadas TN, Herz J, Hynes RO, Schaefer EJ, Wagner DD: Absence of P-selectin delays fatty streak formation in mice. J Clin Invest 1997;99:1037-1043.
16. Dong ZM, Chapman SM, Brown AA, Frenette PS, Hynes RO, Wagner DD: The combined role of P- and E-selectins in atherosclerosis. J Clin Invest 1998;102: 145-152.
17. Phillips JW, Barringhaus KG, Sanders JM, Hesselbacher SE, Czarnik AC, Manka D, Vestweber D, Ley K, Sarembock IJ: Single injection of P-selectin or P-selectin glycoprotein ligand-1 monoclonal antibody blocks neointima formation after arterial injury in apolipoprotein E-deficient mice. Circulation 2003;107:2244-2249.
18. Gu L, Okada Y, Clinton SK, Gerard C, Sukhova GK, Libby P, Rollins BJ: Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. Mol Cell 1998;2:275-281.
19. Boring L, Gosling J, Cleary M, Charo IF: Decreased lesion formation in CCR2-/-mice reveals a role for chemokines in the initiation of atherosclerosis. Nature 1998;394:894-897.
20. Inoue S, Egashira K, Ni W, Kitamoto S, Usui M, Otani K, Ishibashi M, Hiasa K, Nishida K, Takeshita A: Anti-monocyte
21. chemoattractant protein-1 gene therapy limits progression and destabilization of established atherosclerosis in apolipoprotein E-knockout mice. Circulation 2002;106:2700-2706.
22. Ross R: The pathogenesis of atherosclerosis: a perspective of the 1990s. Nature 1993;362:801-809.
23. Beutler B, Cerami A: The biology of cachectin/TNF-a primary mediator of the host response. Annu Rev Immunol 1989;7:625-655.
24. Couffinhal T, Duplaa C, Labat L, Lamaziere JM, Moreau C, Printseva O, Bonnet J: Tumor necrosis factor-alpha stimulates ICAM-1 expression in human vascular smooth muscle cells. Arterioscler Thromb 1993;13:407-414.
25. de Groot AA, Mathy MJ, van Zwieten PA, Peters SL: Antioxidant activity of nebivolol in the rat aorta. J Cardiovasc Pharmacol 2004;43:148-153.
26. Cominacini L, Fratta PA, Garbin U, Nava C, Davoli A, Criscuoli M, Crea A, Sawamura T, Lo C, V: Nebivolol and its 4-keto derivative increase nitric oxide in endothelial cells by reducing its oxidative inactivation. J Am Coll Cardiol 2003;42:1838-1844.
27. Brehm BR, Bertsch D, von Fallois J, Wolf SC: Beta-blockers of the third generation inhibit endothelin-1 liberation, mRNA production and proliferation of human coronary smooth muscle and endothelial cells. J Cardiovasc Pharmacol 2000;36:S401-S403.
28. Mollnau H, Schulz E, Daiber A, Baldus S, Oelze M, August M, Wendt M, Walter U, Geiger C, Agrawal R, Kleschyov AL, Meinertz T, Munzel T: Nebivolol prevents vascular NOS III uncoupling in experimental hyperlipidemia and inhibits NADPH oxidase activity in inflammatory cells. Arterioscler Thromb Vasc Biol 2003;23:615-621.
29. Oelze M, Daiber A, Brandes R, Hortmann M, Wenzel P, Hink U, Schulz E, Mollnau H, von Sandersleben A, Kleschyov AL, Mulsch A, Li H, Forstermann U, Munzel T: Nebivolol inhibits superoxide formation by NADPH oxidase and endothelial dysfunction in angiotensin II-treated rats. Hypertension 2006;48:677-684.
30. Mason RP, Kalinowski L, Jacob RF, Jacoby AM, Malinski T: Nebivolol reduces nitroxidative stress and restores nitric oxide bioavailability in endothelium of black Americans. Circulation 2005;112:3795-3801.
31. Falciani M, Rinaldi B, D'Agostino B, Mazzeo F, Rossi S, Nobili B, Rossi F, Filippelli A: Effects of nebivolol on human platelet aggregation. J Cardiovasc Pharmacol 2001;38:922-929.
32. Celik T, Yuksel UC, Iyisoy A, Kursaklioglu H, Ozcan O, Kilic S, Ozmen N, Isik E: Effects of nebivolol on platelet activation in hypertensive patients: A comparative study with metoprolol. Int J Cardiol 2006; in press.